1 is a viral protein of 86 amino acids encoded by two exons, which plays a crucial role in the replication of the HIV-1 virus (1, 2). The sequence containing the first 72 amino acids, encoded by exon 1, exhibits the full trans-activating activity, whereas the exon 2-encoded 14 amino acid C-terminal sequence is important for the binding to membrane integrins (3). During the initial phase of infection, large amounts of HIV-1 Tat, together with other regulatory proteins, are synthesized and released from HIV-1-infected cells (4, 5). HIV-1 Tat can then translocate across the cell membrane and localize in the nucleus of uninfected cells where it drives virus replication (3). In addition, HIV-1 Tat modulates the expression of many genes regulating important functions such as cell survival and growth, inflammation, and angiogenesis (2). Frequently HIV-1 infection is associated with brain damage (6) characterized by cerebral atrophy, neuronal loss, gliosis, infiltration of inflammatory cells, and microglial activation (7, 8) . All these pathological changes are accompanied by severe cognitive and motor abnormalities; neurological symptoms begin with difficulty in concentration, forgetfulness, and behavioral abnormalities, collectively known as AIDS dementia complex, subsequently progressing to florid dementia, motor impairment, coma, and death (9, 10). Marijuana, a mixture of the leaves and flowering tops of Cannabis sativa, has been used for centuries by mankind to alleviate the symptoms of a wide range of health problems, including mental disorders (11). The pharmacological effects of psychoactive cannabinoids, including ⌬ 9 -tetra-hydrocannabinol, the main psychotropic component of marijuana, depend on the interaction with specific G protein-coupled receptors. Two cannabinoid receptors, named CB 1 and CB 2 , have been so far identified (for review, see Ref. 12). CB 1 receptors are mainly expressed in the central and peripheral nervous systems (13, 14), whereas CB 2 receptors have been identified in cells of the immune system (15) and in C6 cells, a rat glioma cell line (16). Anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG) have been proposed as the endogenous ligands of cannabinoid receptors (17) (18) (19) (20) . The endogenous cannabinoid (endocannabinoid) system, i.e. the cannabinoid receptors and their endogenous ligands, seems to play a role in neuroprotection, as suggested by the up-regulation of CB 1 receptor expression and the elevated concentrations of endocan-* This work was supported by Grant 3933 from Ministero Università e Ricerca Scientifica e Tecnologica (to V. D. M). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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ʈ To whom correspondence may be addressed: Via Campi Flegrei 34, Comprensorio Olivetti, Ed. 70, 80078 Pozzuoli, Naples, Italy. Tel.: 39-081-8675093; Fax: 39-081-8041770; E-mail: vdimarzo@icmib.na.cnr.it. ** To whom correspondence may be addressed: Via D. Montesano 49, 80131 Naples, Italy. Tel.: 39-081-678429; Fax: 39-081-678403; E-mail: iuvone@unina.it. 1 The abbreviations used are: HIV-1 Tat, human immunodeficiency virus-1 Tat; NO, nitric oxide; iNOS, inducible nitric oxide synthase; IFN-␥, interferon-␥; anandamide, arachidonoylethanolamide, AEA; ACEA, arachidonyl-2Ј-chloroethylamide/(all Z)-N-(2-chloroethyl) -5,8, 11,14- nabinoids in some in vivo models of neurodegeneration and brain injury (21) (22) (23) (24) . Recent findings have demonstrated that cannabinoids are able to down-regulate the production of nitric oxide (NO), a short-lived mediator produced by the L-arginine/NO pathway, in macrophages (25, 26) and in rat microglial and glial cells (27, 28) . In the brain, NO is produced by both the constitutive isoform of NO synthase (cNOS) found primarly in neurons (29) and astroglial cells (30) , and the inducible isoform of NO synthase (iNOS) expressed in stimulated astrocytes (31) , in a human astrocytoma cell-line (32) , and in rat C6 cells (28) . NO produced by cNOS in picomolar amounts mediates several physiological effects in the central nervous system, such as neurotransmission (33, 34) , whereas NO generated by iNOS in nanomolar amounts under pathological conditions is a cytotoxic mediator involved in several central nervous system disorders, including inflammatory, infectious, traumatic, and degenerative diseases (35, 36) .
Recently, activated glial cells have also been proposed to play an active role in many neurodegenerative pathologies (37) (38) (39) through the production and release of several pro-inflammatory and cytotoxic mediators (40, 41) , including nitric oxide (28) .
The aim of this study was to evaluate the role of the endocannabinoid system in the control of NO release and cytotoxicity both induced by HIV-1 Tat protein in C6 cells and to assess whether this insult affects endocannabinoid action and homeostasis. Our study casts further light on the role of NO as a potential neurotoxic mediator and on the molecular basis of cannabinoid neuroprotective actions.
EXPERIMENTAL PROCEDURES
Tat Protein Chemical Synthesis-HIV-1 Tat (1-86) was chemically synthesized by step-by-step solid phase peptide synthesis following the Fmoc/1-hydroxybenzotriazole/N,NЈ-dicyclohexylcarbodiimide methodology as previously described (42) . The crude material isolated after trifluoroacetic acid cleavage was purified by semi-preparative reversedphase-HPLC and characterized by analytical RP-HPLC (purity Ͼ 95%), time-of-flight matrix-assisted laser desorption ionization, and electrospray ionization mass spectrometry. The protein was used throughout the experiments without further manipulations dissolved in pyrogenfree distillated water.
Cell Culture and Treatments-C6 rat glioma cells (American Type Culture Collection CCL-107) were grown in Petri dishes (10 cm diameter) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, 100 g/ml streptomycin at 37°C in 5% CO 2 /95% air. Confluent cells were detached by trypsin/EDTA (1:25 v/v), counted, and plated in 24 multiwell plates at a density of 2.5 ϫ 10 5 cells/well and allowed to adhere for 24 h at 37°C. Thereafter, the medium was replaced with fresh medium to a final volume of 1 ml, and cells were treated with interferon-␥ (IFN-␥, 100 units/ml) for 16 -18 h. After this time cells were stimulated with HIV-1 Tat protein (500 ng/ml) for a further 24 h according to Polazzi et al. (43) . In preliminary experiments, the concentration-dependent effect of HIV-1 Tat (100 -500-1000 ng/ml) was investigated, and 1000 ng/ml of this protein, in addition to IFN-␥ (100 units/ml), was chosen as the stimulus to be used in the following experiments. and the selective CB 2 antagonist SR144528 (10 Ϫ9 -10 Ϫ6 M) were given 30 min before the agonists. All the test compounds were given in 100 l of volume. In some experiments, to test the hypothesis that NO may regulate cannabinoid receptor expression, cells were incubated for 24 h in the presence of the NO donor GSNO (10
Nitrite Assay-NO production was measured as the stable metabolite nitrite (NO 2 Ϫ ) accumulated in the incubation medium of C6 cells after 24 h following Tat ϩ IFN-␥ addition, using a spectrophotometric assay based on Griess reaction as previously described (44) .
Preparation of Cytosolic Fractions-Extracts of C6 cells stimulated for 24 h with Tat (100 -500-1000 ng/ml) ϩ IFN-␥ (100 units/ml) in the presence or absence of WIN 55,212,2 (10 Ϫ9 -10 Ϫ6 M) and with WIN 55,212-2 (10 Ϫ7 M) plus both CB 1 and CB 2 receptor antagonists (10
or in other experiments extracts of C6 treated for 24 h with the NO donor, GSNO (100 M), were prepared as previously described (28) . Briefly, harvested cells (2 ϫ 10 7 ) were washed twice with ice-cold phosphate-buffered saline and centrifuged at 180 ϫ g for 10 min at 4°C. The cell pellet was resuspended in 100 l of ice-cold hypotonic lysis buffer (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM phenylmethylsulphonyl fluoride, 1.5 g/ml soybean trypsin inhibitor, 7 g/ml pepstatin A, 5 g/ml leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and incubated in ice per 15 min. The cells were lysed by rapid passage through a syringe needle five or six times, and the cytoplasmic fraction was then obtained by centrifugation at 13000 ϫ g for 1 min.
Western Blot Analysis-Immunoblotting analysis of iNOS protein and CB 1 and CB 2 receptors were performed on cytosolic fraction of C6 cells treated as above described. Cytosolic fraction proteins were mixed with gel loading buffer (50 mM Tris/10% SDS/10% glycerol 2-mercaptoethanol/2 mg bromphenol per ml) in a ratio of 1:1, boiled for 3 min, and centrifuged at 10,000 ϫ g for 10 min. Protein concentration was determined, and equivalent amounts (50 g) of each sample were electrophoresed in a 10% discontinous polyacrilamide minigel. The proteins were transferred onto nitrocellulose membrane, according to the manufacturer's instructions (Bio-Rad). The membranes were saturated by incubation at 4°C overnight with 10% nonfat dry milk in phosphatebuffered saline and then incubated with mouse anti-iNOS antibody (1:1000) (Transduction Laboratories) and rabbit polyclonal anti-CB 1 or anti-CB 2 antibody (1:500) (Cayman) for 1 h at room temperature. The membranes were washed three times with 1% Triton X-100 in phosphate-buffered saline and then incubated with anti-mouse or antirabbit immunoglobulins coupled to peroxidase (1:2000) (Amersham Biosciences). The immune complexes were developed using enhanced chemiluminescence detection reagents (Amersham Biosciences) according to the manufacturer's instructions and exposed to Kodak X-Omat film. The protein bands of iNOS, CB 1 , and CB 2 on x-ray film were scanned and densitometrically analyzed with a GS-700 imaging densitometer.
MTT Viability Assay-Cell viability was measured by MTT assay, according to Esposito et al. (45) . The cells were plated in 96-well culture plates at the density of 5 ϫ 10 3 cells/ml/well and allowed to adhere at 37°C. Thereafter, the medium was replaced with 50 l of fresh medium, and cells were incubated with Tat (1000 ng/ml) ϩ IFN␥ (100 units/ml) for 24 h in the presence or absence of WIN 55,212,2 (10 Ϫ9 -10 Ϫ6 M) and with WIN 55,212-2 (10 Ϫ7 M) plus either CB 1 or CB 2 receptor antagonists (10 Ϫ9 -10 Ϫ6 M). After this time, MTT (25 l) was added in each well, and cells were incubated for additional 3 h at 37°C. Afterward, cells were lysed and the dark blue crystals solubilized with 125 l of a solution containing 20% sodium dodecylsulphate in 1:1 deionized water/dimethylformamide, with an adjusted pH of 4.5, and wells were incubated overnight. The cell viability in response to the treatment with test compounds was measured by a spectrophotometric assay at 620 nm by detecting the complex MTT-formazan salt-conjugated and was expressed as % of cell viability ϭ (OD treated/OD control) ϫ 100.
Total RNA Isolation and RT-PCR Analysis-Total RNA from C6 cells was extracted using Trizol reagent according to the manufacturer's recommendations (Invitrogen). Following extraction, RNA was precipitated using ice-cold isopropanol, resuspended in diethyl pyrocarbonate (Sigma)-treated water, and its integrity was verified following separation by electrophoresis into a 1% agarose gel containing ethidium bromide. RNA was further treated with RNase-free DNase I (Ambion DNA-free TM kit) according the manufacturer's recommendations to digest contaminating genomic DNA and to subsequently remove the DNase and divalent cations.
The expression of mRNAs for GAPDH (glyceraldehyde-3-phosphate dehydrogenase), CB 1 , and CB 2 receptors was examined by reverse transcription coupled to the polymerase chain reaction (RT-PCR). Total RNA was reverse-transcribed using oligo dT primers. DNA amplifications were carried out in PCR buffer (Q-Biogen) containing 2 l of cDNA, 500 M deoxynucleotide tris-phosphate, 2 mM MgCl 2 , 0.8 M of each primer, and 0.5 units Taq polymerase (Q-Biogen). The thermal reaction profile consisted of a denaturation step at 94°C for 1 min, annealing at 60°C for 1 min, and an extension step at 72°C for 1 min. A final extension step of 10 min was carried out at 72°C. The PCR cycles ranging from 20 to 40 were observed to be optimal and in the linear portion of the amplification curve (data not shown). Reaction was performed in a PE Gene Amp PCR System 9600 (PerkinEmer Life Sciences). After reaction, the PCR products were electrophoresed on a 2% agarose gel containing ethidium bromide for UV visualization.
The specific human oligonucleotides were synthesized on the basis of cloned rat cDNA sequences of GAPDH, CB 1 , and CB 2 . For GAPDH, the primers sequences were 5Ј-CCCTTCATTGACCTCAACTACATGGT-3Ј
(nt 208 -233; sense) and 5Ј-GAGGGCCATCCACAGTCTTCTG-3Ј (nt 655-677; antisense). The CB 1 sense and antisense primers were 5Ј-GATGTCTTTGGGAAGATGAACAAGC-3Ј (nt 365-373) and 5Ј-AGACGTGTCTGTGGACACAGACATGG-3Ј (nt 460 -468), respectively. For CB 2 , the primer sequences were 5Ј-CCCATGCAGGA(G/T)TACAT-GATCCTGAG-3Ј (nt 20 -29; sense) and 5Ј-CTCCGC(A/C)G(A/G)AAGC-CCTC(A/G)TAC-3Ј (nt 64 -70; antisense). The expected sizes of the amplicons were 470 bp for GAPDH, 309 bp for CB 1 , and 150 bp for CB 2 . The GAPDH housekeeping gene expression was used to evaluate any variation in the RNA content and cDNA synthesis in the different preparations. No PCR products were detected when the reverse transcriptase step was omitted (data not shown).
Anandamide Uptake by C6 Cells-Confluent C6 cells in 6-well dishes after treatment with either vehicle or HIV-1 Tat (1000 ng/ml) ϩ IFN-␥ (100 units/ml) were incubated for either 10 Anandamide Hydrolysis by C6 Cell Membranes-Mitochondrial membranes were prepared from C6 cells treated with either vehicle or HIV-1 Tat (500 ng/ml) ϩ IFN-␥ (100 units/ml), as described previously (47) , and used as a source of fatty acid amide hydrolase (FAAH, also known as anandamide amidohydrolase) to carry out enzymatic hydrolysis assays with [
14 C]anandamide (5 mCi/mmol, 40000 cpm, 10 M) (47). [
14 C]Ethanolamine produced from [ 14 C]anandamide hydrolysis was extracted from the incubation mixtures by extraction with chloroform/methanol 2:1 (by volume), quantified by liquid scintillation counting, and used to measure the rate of the enzymatic reaction.
Materials-All chemicals for solid phase peptide synthesis (Fmocprotected aminoacids, resins, and condensing agents) were from Novabiochem (Laufelfingen, Switzerland) and Applied Biosystem (Foster City, CA); solvents for HPLC analysis and purification and trifluoroacetic acid and scavengers for peptide cleavage were from Sigma. Columns for protein characterization and purification were from Phenomenex (Torrance, CA).
All the materials for cell culture were purchased from BioWhittaker (Caravaggio, BG, Italy). Fetal calf serum was from Hyclone. IFN-␥ was from PBL Biomedical Laboratories (Vinci-Biochem, Vinci, Italy). WIN 55,212-2, ACEA, and JWH 015 were from Tocris Cookson (Bristol, UK). SR141716A and SR144528 were a kind gift from Drs. Madeleine Mossè and Francis Barth from SANOFI-Recerche.
Statistical Analysis-Results were expressed as the mean Ϯ S.E. of n experiments. Statistical analysis was determined with ANOVA and multiple comparisons were performed by Bonferroni's test, with p Ͻ 0.05 considered significant.
RESULTS

Concentration-dependent Effect of HIV-1 Tat Protein on Nitrite Production and iNOS Expression-Unstimulated
6 cells). The effect of HIV-1 Tat on nitrite production was studied by incubation of C6 cells with IFN-␥ (100 units/ml) for 16 -18 h, after which the cells were stimulated further for 24 h with HIV-1 Tat. The incubation of cells with IFN-␥ (100 units/ml) alone for 16 -18 h did not induce a significant increase of nitrite production (7.6 Ϯ 1.5 nmol/10 6 cells) in comparison to unstimulated cells; stimulation with Tat protein (100 -500-1000 units/ ml) for a further 24 h resulted in a significant and concentrationdependent increase of nitrite production in the cell medium (9.3 Ϯ 0.8, 19.2 Ϯ 1.3, and 28.0 Ϯ 2.5 nmol/10 6 cells, respectively). The presence of iNOS in the cytosolic fractions was investigated by immunoblotting analysis. A basal level of iNOS was detectable in the cytosolic fractions of unstimulated cells; after 16 -18 h of IFN-␥ (100 units/ml) treatment iNOS expression slightly increased, whereas HIV-1 Tat protein (100 -500-1000 ng/ml) stimulation of cells for a further 24 h markedly increased iNOS expression in a concentration-dependent fashion (Fig. 1) .
Effect (Fig. 4) . 29.0 Ϯ 1.9, and 27.0 Ϯ 2.0 nmol/10 6 cells) by stimulated cells (Fig. 5, A and B) .
Effect of Selective CB 1 and CB 2 Agonist on Nitrite Production-The
HIV- (Fig. 6) . (Fig. 7A) . Quantitative RT-PCR analysis showed that the inhibitory effect was exerted at the transcriptional level, because the amounts of CB 1 , but not CB 2 , mRNA transcripts were significantly reduced in cells treated with IFN-␥ ϩ HIV-1 Tat (Fig. 7B and data not shown) .
Effect of the NO-donor, GSNO, on CB 1 and CB 2 Receptor Protein Expression-Treatment of C6 cells with GSNO (10
Ϫ4
M), an NO donor, for 24 h resulted in a significant decrease of CB 1 , but not CB 2 , receptor expression (47.3% of the expression respective to untreated control cells, as shown by densitometric analysis) (Fig. 8) . 
Effect of HIV-1 Tat on Anandamide Inactivation by C6
DISCUSSION
In this study we show that the HIV-1 Tat protein is able to induce iNOS protein expression and nitrite production in the astroglial-derived cell line, C6 (rat glioma cells), pre-incubated with IFN-␥. Our findings are in agreement with the results reported by Polazzi et al. (43) in rat microglial cells. Overproduction of nitrite by the activated glia may amplify an inflammatory process leading to neuronal death and, in turn, to neurodegeneration, such as in HIV-related dementia complex, frequently observed in HIV-affected patients (48) .
The results of our study demonstrate that HIV-1 Tat-induced iNOS protein expression and nitrite production in C6 cells were inhibited, in a concentration-dependent fashion, and to a partial extent by WIN 55,212-2, a dual CB 1 and CB 2 receptor agonist. HIV-1 Tat-induced nitrite production was also partially inhibited by ACEA, a selective CB 1 agonist, but not by JWH-015, a selective CB 2 agonist. Furthermore, WIN 55,212-2-induced inhibition of both iNOS protein expression and nitrite production was reversed by SR141716A, a CB 1 receptor antagonist, whereas it resulted unaffected by the CB 2 receptor antagonist, SR1445528. These data indicate that the inhibition of iNOS protein expression and nitrite production in C6 cells stimulated by HIV-1 Tat is selectively mediated by CB 1 receptor activation.
Our results support our previous suggestion (16) that the inhibition by cannabinoids of iNOS protein expression and nitrite in lipopolysaccharide-treated C6 cells is selectively mediated by CB 1 receptors (28) . In the present study we also observed that HIV-1 Tat was toxic to C6 cells. Previously, Gavril et al. (49) showed that HIV-Tat protein was toxic to differentiated PC12 cells, a rat neuronal cell-line. Therefore, our results extend our knowledge of HIV-1 Tat cytotoxic effects also to a glial-derived cell-line. More importantly, we found that treatment of C6 cells with WIN 55,212-2 resulted in a potent protective action against cell death induced by HIV-1 Tat. This effect of WIN 55,212-2 appears to be selectively mediated by CB 1 receptors because it was attenuated by a CB 1 , but not CB 2 , receptor selective antagonist. We suggest that stimulation of CB 1 receptors leads to inhibition of HIV-1 Tatinduced cytotoxicity through the inhibition of the HIV-1 Tatinduced overproduction of NO, which has been found to have a toxic action on C6 cells (50, 51) . Because, glial cell activation seems to play an important role in neurodegeneration (37) (38) (39) , through the release of several cytotoxic mediators (40, 41) , including NO (28), it can be hypothesized that cannabinoids, by inhibiting iNOS protein expression and NO overproduction, may protect neurons from HIV-1 Tat-induced damage. Such an effect, in the long term, may eventually result in a possible beneficial effect on AIDS dementia complex.
In this study we also present unprecedented evidence on the regulation of the endocannabinoid system by HIV-1 Tat. We found that HIV-1 Tat treatment of C6 cells down-regulates the CB 1 , but not CB 2 , receptor at the transcriptional level. This effect is probably related to HIV-1 Tat-induced overproduction of NO because the NO donor GSNO reduced CB 1 receptor expression in C6 cells. Because we have shown here that CB 1 receptor stimulation leads to an inhibition of HIV-1 Tat-induced NO release, it is possible that CB 1 receptor agonists also reduce HIV-1 Tat-induced down-regulation of CB 1 receptor expression. We could not test this hypothesis because longterm stimulation of CB 1 receptors is known to lead to their down-regulation and desensitization through several mechanisms (52, 53) . Therefore, it would not have been easy to interpret measures of CB 1 receptor expression after 24 h co-incubation of C6 cells with HIV-1 Tat and WIN 55,212-2 (or ACEA).
In view of the multi-faceted neuroprotective effects exerted by the stimulation of CB 1 receptors (24), in many cell lines including C6 cells (54), we can speculate that part of HIV-1 Tat-induced neuronal damage is due to down-regulation of a neuroprotective endocannabinoid tone. However, the possible neurotoxic effect of HIV-1 Tat-induced down-regulation of CB 1 receptors might be minimized by HIV-1 Tat-induced inhibition of the cellular uptake and consequent degradation of the endocannabinoid anandamide by C6 cells, which was shown here for the first time. It is noteworthy that this effect of HIV-1 Tat, unlike the other effects described in this study, does not appear to be correlated to HIV-1 Tat-induced NO overproduction because NO has been found to slightly enhance, rather than inhibit, endocannabinoid cellular uptake in C6 cells (46, 52) . Thus, it is conceivable that the increase of NO release by HIV-1 Tat prevented us from observing an even higher inhibitory action by HIV-1 Tat on anandamide reuptake. At any rate, even a small inhibitory effect of HIV-1 Tat on anandamide re-uptake by C6 cells is likely to result in a significant enhancement of the extracellular amounts of endocannabinoids available for CB 1 stimulation and, if occurring also in glial cells in vivo, might compensate in part for the down-regulation of CB 1 expression by HIV-1 Tat.
In conclusion, here we have presented for the first time data indicating that the endocannabinoid system protects C6 glioma cells from HIV-1 Tat-induced overproduction of NO and cell damage. Moreover, here we show for the first time that HIV-1 Tat inhibits CB 1 receptor expression and increases the amounts of extracellular endocannabinoids, thus regulating the levels of at least two components of the endocannabinoid system. Future in vivo studies should be addressed at establishing the relevance of these findings to the pathological effects of HIV-1 infection in the central nervous system, including AIDS dementia complex.
